Under the agreement, Agilent will make a payment to Invitrogen for an undisclosed amount and discontinue sales of RNase H
minus reverse transcriptase products.
(Montreal, Canada) in consortium with Rutgers University (New Brunswick, NJ) and the University of Pittsburgh (Pittsburgh, PA) has been selected by the National Institutes of Health to receive more than $4.6 M over the next five years for a project "HIV RNase H natural product inhibitors" to develop novel HIV therapeutics directed at the under-explored HIV target ribonuclease H (RNase H).
Parniak, Professor of Molecular Genetics & Biochemistry at the University of Pittsburgh and Principal Investigator of this multi-team research effort, has nearly 20 years experience in HIV research and is regarded as a thought leader in the discovery of drugs targeting HIV RNase H. Dr.
We are also indebted to our shareholders who supported us over the years, especially in acquiring the patent in 2006 that describes the compounds that inhibit HIV RNase H. This collaborative research project with Drs.
In accordance with the Invitrogen manual, eDNA was synthesized, by using random hexamers (Takara Bio Inc., Kyoto, Japan) and Superscript III (Invitrogen, Carlsbad, CA, USA) lacking RNase H
activity, at 50[degrees]C for 1 h.
I exposed ethidium bromide-containing serum to RNase H, which selectively degrades RNA in RNA-DNA heteroduplex molecules.
I treated ethidium bromide-containing normal human serum with these three concentrations of RNase H. This endoribonuclease specifically degrades the RNA strand of a RNA-DNA hybrid to produce 5' phosphate-terminated oligoribonucleotides and single-stranded DNA.
Inhibition of human immunodeficiency virus type 1 RNase H by sulfated polyanions.
Millenia is also pursuing its patent application (pending) for inhibitors of HIV RNase H
, as previously mentioned on Feb.
In October 2001, Invitrogen filed suit against Incyte Genomics alleging infringement of three patents relating to the use of reverse transcriptase with no RNase H
activity for preparing complimentary DNA from RNA.
Central components of the patent suite are intellectual property surrounding RNase H
and second generation antisense inhibitors designed to work through the RNase H
mechanism of action.